nicole, Author at FACIT

New Innovative Cancer Technology Wins 2023 Falcons’ Fortunes Pitch Competition

Posted on March 31, 2023 (September 25, 2023)

March 31, 2023 – The winning pitch for the 10th anniversary Falcons’ Fortunes pitch competition and the $100,000 Ernsting Entrepreneurship Award was delivered by Dr. Sumaiyah Rehman, co-founder and CEO of DTPx Therapeutics.

FACIT generates $1.5 billion in follow-on investment

Posted on March 29, 2023 (September 15, 2024)

March 29, 2023 – FACIT announced $1.5 billion in follow-on investment attracted to its portfolio of cancer biotechnology start-ups in Ontario, a significant milestone for life science commercialization in Canada.

CTRL Therapeutics, a FACIT-backed start-up, raises US$10M to develop autologous cell therapy for patients living with cancer

Posted on March 23, 2023 (October 20, 2025)

March 23, 2023 – CTRL Therapeutics (“CTRL”) closed a seed financing round to develop a tumor-infiltrating lymphocyte (TIL) therapy for solid tumours. CTRL is advancing novel, non-invasive and less costly therapies for patients living with cancer.

Registration is now open for FACIT Falcons’ Fortunes pitch competition and reception

Posted on February 21, 2023 (April 28, 2023)

February 21, 2023 – This year marks the 10th anniversary of the FACIT Falcons’ Fortunes pitch competition! Be part of the audience and watch the six finalists pitch their Ontario oncology innovations.

Happy Holidays from the FACIT team!

Posted on December 5, 2022 (December 5, 2022)

December 5, 2022 – Your friends at FACIT wish you a healthy and relaxing holiday season. It has been a productive year and our team continues to grow the province’s biotech ecosystem through the commercialization of Ontario’s most promising cancer innovations.

FACIT’s Prospects Fund fuels women’s health and brain cancer therapies for Ontario patients

Posted on September 28, 2022 (July 31, 2023)

September 28, 2022 – FACIT congratulates Ontario-based start-ups Hyivy Health and HDAX Therapeutics as the latest recipients of capital through its Prospects Oncology Fund. Selected among a top-tier pool of applicants, these Ontario-based innovations illustrate excellent potential to benefit patients with cancer.

FACIT’s David O’Neill shares strategy for Ontario intellectual property

Posted on June 16, 2022 (September 28, 2022)

June 16, 2022 – The paper “How to boost Ontario’s life sciences IP to help patients and the economy” discusses the importance of seed-stage investing and commercialization-venture partnerships to reap the benefits of taxpayers’ investment in post-secondary education and health research.

FACIT invests in OICR’s groundbreaking approaches to integrated drug discovery and cancer informatics

Posted on April 28, 2022 (October 4, 2022)

April 28, 2022 – April 27, 2022 – FACIT announced two recent strategic investments from its Prospects Oncology Fund in innovations arising from renowned cancer experts at the Ontario Institute for Cancer Research (OICR): Dr. Rima Al-awar, Head of Therapeutic Innovation and Drug Discovery, and Dr. Lincoln Stein, Head of Adaptive Oncology.

FACIT announces winner of 2022 Falcons’ Fortunes pitch competition on World Cancer Day

Posted on February 4, 2022 (October 4, 2022)

February 4, 2022 – February 4, 2022 – FACIT is pleased to announce the 2022 winner of its Falcons’ Fortunes pitch competition: Point Surgical Inc.. Point Surgical was founded as a joint venture between Toronto’s University Health Network, Unity Health Toronto and Light Matter Interaction Inc.

High-potency TIL cell therapy approach reported using CytoFind platform developed by FACIT portfolio company Cellular Analytics

Posted on January 27, 2022 (March 9, 2022)

January 27, 2022 – January 27, 2022 – FACIT congratulates portfolio company Cellular Analytics on a recent publication by its CSO, Dr. Shana Kelley and collaborators, on the Company’s tumor-infiltrating lymphocyte (TIL) therapeutics platform.

Author: nicole

Posts by nicole